Systemic lupus erythematosus laboratory tests: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(5 intermediate revisions by 2 users not shown)
Line 5: Line 5:


== Overview ==
== Overview ==
Laboratory findings consistent with the diagnosis of systemic lupus erythematosus include [[autoantibodies]] elevation of [[ANA]], [[anti-dsDNA antibody]], [[anti-SM antibody]] and [[antiphospholipid antibodies]], and decrease of [[complement]] levels. Non specific laboratory findings include mild [[pancytopenia]], elevated levels of [[creatinine]] and [[proteinuria]] due to [[renal failure]] (secondary to [[nephritis]]), elevated levels of [[ESR]] and [[C-reactive protein|CRP]] as [[Acute phase reactant|acute phase reactants]], decreased level of [[Complement|complements]], and positive [[Coombs test|direct coombs test]].
Laboratory findings consistent with the diagnosis of systemic lupus erythematosus include [[autoantibody]] elevation of [[ANA]], [[anti-dsDNA antibody]], [[anti-SM antibody]], and [[antiphospholipid antibodies]], and a decrease in [[complement]] levels. Nonspecific laboratory findings include mild [[pancytopenia]], elevated levels of [[creatinine]] and [[proteinuria]] due to [[renal failure]] (secondary to [[nephritis]]), elevated levels of [[ESR]] and [[C-reactive protein|CRP]] as [[Acute phase reactant|acute phase reactants]], decreased level of [[Complement|complements]], and positive [[Coombs test|direct Coombs test]].


== Laboratory tests ==
== Laboratory tests ==
Laboratory findings consistent with the diagnosis of systemic lupus erythematosus include [[autoantibodies]] elevation of [[ANA]], [[anti-dsDNA antibody]], [[anti-SM antibody]] and [[antiphospholipid antibodies]], and decrease of [[complement]] levels.<ref name="pmid2646863">{{cite journal |vauthors=Tan EM |title=Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology |journal=Adv. Immunol. |volume=44 |issue= |pages=93–151 |year=1989 |pmid=2646863 |doi= |url=}}</ref><ref name="pmid23316252">{{cite journal |vauthors=Willitzki A, Hiemann R, Peters V, Sack U, Schierack P, Rödiger S, Anderer U, Conrad K, Bogdanos DP, Reinhold D, Roggenbuck D |title=New platform technology for comprehensive serological diagnostics of autoimmune diseases |journal=Clin. Dev. Immunol. |volume=2012 |issue= |pages=284740 |year=2012 |pmid=23316252 |pmc=3536031 |doi=10.1155/2012/284740 |url=}}</ref><ref name="pmid24864270">{{cite journal |vauthors=Li J, Leng X, Li Z, Ye Z, Li C, Li X, Zhu P, Wang Z, Zheng Y, Li X, Zhang M, Tian XP, Li M, Zhao J, Zhang FC, Zhao Y, Zeng X |title=Chinese SLE treatment and research group registry: III. association of autoantibodies with clinical manifestations in Chinese patients with systemic lupus erythematosus |journal=J Immunol Res |volume=2014 |issue= |pages=809389 |year=2014 |pmid=24864270 |pmc=4017718 |doi=10.1155/2014/809389 |url=}}</ref><ref name="pmid25449682">{{cite journal |vauthors=Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O, Komisar O, Slonimsky E, Klang E, Lotan E, Welt M, Marai I, Shina A, Amital H, Shoenfeld Y |title=A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients |journal=Autoimmun Rev |volume=14 |issue=1 |pages=75–9 |year=2015 |pmid=25449682 |doi=10.1016/j.autrev.2014.10.003 |url=}}</ref><ref name="pmid16420554">{{cite journal |vauthors=Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA |title=International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) |journal=J. Thromb. Haemost. |volume=4 |issue=2 |pages=295–306 |year=2006 |pmid=16420554 |doi=10.1111/j.1538-7836.2006.01753.x |url=}}</ref><ref name="pmid18075790">{{cite journal |vauthors=Truedsson L, Bengtsson AA, Sturfelt G |title=Complement deficiencies and systemic lupus erythematosus |journal=Autoimmunity |volume=40 |issue=8 |pages=560–6 |year=2007 |pmid=18075790 |doi=10.1080/08916930701510673 |url=}}</ref><ref name="pmid15593352">{{cite journal |vauthors=Benito-Garcia E, Schur PH, Lahita R |title=Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests |journal=Arthritis Rheum. |volume=51 |issue=6 |pages=1030–44 |year=2004 |pmid=15593352 |doi=10.1002/art.20836 |url=}}</ref>
Laboratory findings consistent with the diagnosis of systemic lupus erythematosus include [[autoantibody]] elevation of [[ANA]], [[anti-dsDNA antibody]], [[anti-SM antibody]] and [[antiphospholipid antibodies]]. However, decrease of [[complement]] levels is a common finding in SLE.<ref name="pmid2646863">{{cite journal |vauthors=Tan EM |title=Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology |journal=Adv. Immunol. |volume=44 |issue= |pages=93–151 |year=1989 |pmid=2646863 |doi= |url=}}</ref><ref name="pmid23316252">{{cite journal |vauthors=Willitzki A, Hiemann R, Peters V, Sack U, Schierack P, Rödiger S, Anderer U, Conrad K, Bogdanos DP, Reinhold D, Roggenbuck D |title=New platform technology for comprehensive serological diagnostics of autoimmune diseases |journal=Clin. Dev. Immunol. |volume=2012 |issue= |pages=284740 |year=2012 |pmid=23316252 |pmc=3536031 |doi=10.1155/2012/284740 |url=}}</ref><ref name="pmid24864270">{{cite journal |vauthors=Li J, Leng X, Li Z, Ye Z, Li C, Li X, Zhu P, Wang Z, Zheng Y, Li X, Zhang M, Tian XP, Li M, Zhao J, Zhang FC, Zhao Y, Zeng X |title=Chinese SLE treatment and research group registry: III. association of autoantibodies with clinical manifestations in Chinese patients with systemic lupus erythematosus |journal=J Immunol Res |volume=2014 |issue= |pages=809389 |year=2014 |pmid=24864270 |pmc=4017718 |doi=10.1155/2014/809389 |url=}}</ref><ref name="pmid25449682">{{cite journal |vauthors=Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O, Komisar O, Slonimsky E, Klang E, Lotan E, Welt M, Marai I, Shina A, Amital H, Shoenfeld Y |title=A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients |journal=Autoimmun Rev |volume=14 |issue=1 |pages=75–9 |year=2015 |pmid=25449682 |doi=10.1016/j.autrev.2014.10.003 |url=}}</ref><ref name="pmid16420554">{{cite journal |vauthors=Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA |title=International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) |journal=J. Thromb. Haemost. |volume=4 |issue=2 |pages=295–306 |year=2006 |pmid=16420554 |doi=10.1111/j.1538-7836.2006.01753.x |url=}}</ref><ref name="pmid18075790">{{cite journal |vauthors=Truedsson L, Bengtsson AA, Sturfelt G |title=Complement deficiencies and systemic lupus erythematosus |journal=Autoimmunity |volume=40 |issue=8 |pages=560–6 |year=2007 |pmid=18075790 |doi=10.1080/08916930701510673 |url=}}</ref><ref name="pmid15593352">{{cite journal |vauthors=Benito-Garcia E, Schur PH, Lahita R |title=Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests |journal=Arthritis Rheum. |volume=51 |issue=6 |pages=1030–44 |year=2004 |pmid=15593352 |doi=10.1002/art.20836 |url=}}</ref>


=== Laboratory changes in SLE: ===  
=== Laboratory changes in SLE: ===  
Line 15: Line 15:
! style="background: #4479BA; color: #FFFFFF; " |<small><small>Exam type</small></small>
! style="background: #4479BA; color: #FFFFFF; " |<small><small>Exam type</small></small>
! style="background: #4479BA; color: #FFFFFF; " |Lab exam
! style="background: #4479BA; color: #FFFFFF; " |Lab exam
! style="background: #4479BA; color: #FFFFFF; " |result
! style="background: #4479BA; color: #FFFFFF; " |Result
! style="background: #4479BA; color: #FFFFFF; " |clinical correlation
! style="background: #4479BA; color: #FFFFFF; " |Clinical correlation
|-
|-
| rowspan="4" |<small>Hematology</small>
| rowspan="4" |<small>Hematology</small>
Line 54: Line 54:
| style="background: #DCDCDC; " |Urine sediment
| style="background: #DCDCDC; " |Urine sediment
|-
|-
| rowspan="12" |<small>Serology</small>
| rowspan="13" |<small>Serology</small>
| style="background: #DCDCDC; " |[[ANA]]
| style="background: #DCDCDC; " |[[ANA]]
|Elevated
|Elevated
Line 62: Line 62:
| style="background: #DCDCDC; " |Antiphospholipid antibodies
| style="background: #DCDCDC; " |Antiphospholipid antibodies
|
|
* [[Lupus anticoagulant]] [LA]
* [[Lupus anticoagulant]] (LA)
* [[IgG]] and [[IgM]] [[Anti-cardiolipin antibodies|anticardiolipin [aCL] antibodies]]
* [[IgG]] and [[IgM]] [[Anti-cardiolipin antibodies|anticardiolipin (aCL) antibodies]]
* [[IgG]] and [[IgM]] anti-beta2-glycoprotein [GP]
* [[IgG]] and [[IgM]] anti-beta2-glycoprotein (GP)
|
|
* Can be predictive of [[hematologic]] and [[Thromboembolic disease|thromboembolic]] involvement
* Can be predictive of [[hematologic]] and [[Thromboembolic disease|thromboembolic]] involvement
Line 70: Line 70:
| style="background: #DCDCDC; " |[[Complement]] levels
| style="background: #DCDCDC; " |[[Complement]] levels
|
|
* C3: vary between varying between normal to slightly reduced
* C3: Vary between varying between normal to slightly reduced
* C4: reduced
* C4: Reduced
* CH50: reduced
* CH50: Reduced
|
|
* Impaired clearance of [[immune complexes]]
* Impaired clearance of [[immune complexes]]
Line 98: Line 98:
|
|
* Highly specific for SLE
* Highly specific for SLE
* In 70% of patients
* As high as 70% of patients
|-
|-
| style="background: #DCDCDC; " |[[Anti-SM antibody|Anti-SM antibodies]]  
| style="background: #DCDCDC; " |[[Anti-SM antibody|Anti-SM antibodies]]  
Line 104: Line 104:
|
|
* Highly specific for SLE  
* Highly specific for SLE  
* In 30% of patients
* Positive in 30% of patients


* Lack sensitivity
* Lack sensitivity
Line 111: Line 111:
|Elevated
|Elevated
|
|
* In 30% of patients
* Positive in 30% of patients
* More commonly associated with [[Sjögren’s syndrome]]
* More commonly associated with [[Sjögren’s syndrome]]
|-
|-
Line 117: Line 117:
|Elevated
|Elevated
|
|
* In 20% of patients
* Positive in 20% of patients
* More commonly associated with [[Sjögren's syndrome|Sjögren’s syndrome]]  
* More commonly associated with [[Sjögren's syndrome|Sjögren’s syndrome]]  
|-
|-
Line 123: Line 123:
|Elevated
|Elevated
|
|
* In approximately 25 percent of patients with SLE
* Positive in approximately 25% of patients with SLE
* Not specific, always present in patients with [[mixed connective tissue disease]] (MCTD)
* Not specific, always present in patients with [[mixed connective tissue disease]] (MCTD)
|-
|-
Line 132: Line 132:
* Lack specificity for involvement of a particular organ system or disease manifestation
* Lack specificity for involvement of a particular organ system or disease manifestation
|-
|-
|
| style="background: #DCDCDC; " |[[Coombs test|Direct Coombs' test]]
| style="background: #DCDCDC; " |[[Coombs test|Direct Coombs' test]]
|Positive
|Positive
|
|
* Clinically important in the absence of other causes of hemolytic anemia
* Clinically important in the absence of other causes of [[hemolytic anemia]]
|}
|}


Line 143: Line 142:
=== Laboratory exams to distinguish SLE from other diseases ===
=== Laboratory exams to distinguish SLE from other diseases ===
{| class="wikitable"
{| class="wikitable"
!Test
! style="background: #4479BA; color: #FFFFFF; " |Test
!Interpretation
! style="background: #4479BA; color: #FFFFFF; " |Interpretation
|-
|-
|Anti-cyclic citrullinated peptide (CCP) antibodies
| style="background: #DCDCDC; " |Anti-cyclic citrullinated peptide (CCP) antibodies
|
|
* In patients with predominant [[arthralgias]] or [[arthritis]] may help exclude a diagnosis of [[Rheumatoid arthritis|rheumatoid arthritis (RA)]]
* In patients with predominant [[arthralgias]] or [[arthritis]] may help exclude a diagnosis of [[Rheumatoid arthritis|rheumatoid arthritis (RA)]]
* Higher specificity for [[RA]]
* Higher specificity for [[RA]]
|-
|-
|Rheumatoid factor (RF)
| style="background: #DCDCDC; " |Rheumatoid factor (RF)
|
|
* Less diagnostic since only 20 to 30 percent of people with SLE have a positive [[RF]]
* Less diagnostic since only 20 to 30 percent of people with SLE have a positive [[RF]]
* Consider [[RA]]
* Consider [[RA]]
|-
|-
| rowspan="4" |Serological studies for infection
| rowspan="4" style="background: #DCDCDC; " |Serological studies for infection
|
|
* [[Serologic]] testing for [[Human parvovirus B19 infection|human parvovirus B19]]
* [[Serologic]] testing for [[Human parvovirus B19 infection|human parvovirus B19]]
Line 172: Line 171:
* Testing for [[Epstein-Barr virus|Epstein-Barr virus (EBV)]]
* Testing for [[Epstein-Barr virus|Epstein-Barr virus (EBV)]]
|-
|-
|Creatine kinase (CK)
| style="background: #DCDCDC; " |Creatine kinase (CK)
|
|
* Can reflect [[myositis]] (relatively uncommon in patients with SLE)
* Can reflect [[myositis]] (relatively uncommon in patients with SLE)
Line 183: Line 182:
=== A more detailed look into auto-antibodies in SLE ===
=== A more detailed look into auto-antibodies in SLE ===
{| class="wikitable"
{| class="wikitable"
!Antibodies
! style="background: #4479BA; color: #FFFFFF; " |Antibodies
!Prevalence
! style="background: #4479BA; color: #FFFFFF; " |Prevalence
!Association with disease activity
! style="background: #4479BA; color: #FFFFFF; " |Association with disease activity
!Pathogenesis involvement
! style="background: #4479BA; color: #FFFFFF; " |Pathogenesis involvement
|-
|-
|[[ANA]]
| style="background: #DCDCDC; " |[[ANA]]
|80
|80
| -
| -
|[[Cutaneous lupus erythematosus]]
|[[Cutaneous lupus erythematosus]]
|-
|-
|dsDNA
| style="background: #DCDCDC; " |dsDNA
|70
|70
| -/+
| -/+
|[[Lupus nephritis]]
|[[Lupus nephritis]]
|-
|-
|Anti-Sm antibodies
| style="background: #DCDCDC; " |Anti-Sm antibodies
|30
|30
| -
| -
|[[Renal]], [[Neurology|neurologic]], [[vasculitis]] and [[hematologic diseases]]
|[[Renal]], [[Neurology|neurologic]], [[vasculitis]] and [[hematologic diseases]]
|-
|-
|snRNP (U1 RNP)
| style="background: #DCDCDC; " |snRNP (U1 RNP)
|30-40
|30-40
| -
| -
| -
| -
|-
|-
|SSA/Ro
| style="background: #DCDCDC; " |SSA/Ro
|30
|30
| -
| -
|[[Neonatal lupus]]
|[[Neonatal lupus]]
|-
|-
|SSB/La
| style="background: #DCDCDC; " |SSB/La
|20
|20
| -
| -
|[[Neonatal lupus]]
|[[Neonatal lupus]]
|-
|-
|Antiribosomal P protein antibodies
| style="background: #DCDCDC; " |Antiribosomal P protein antibodies
|20
|20
| -
| -
|[[Neuropsychiatry|Neuro-psychiatric]] disease, [[liver disease]]
|[[Neuropsychiatry|Neuro-psychiatric]] disease, [[liver disease]]
|-
|-
|RF
| style="background: #DCDCDC; " |RF
|20
|20
| -
| -

Latest revision as of 19:55, 2 August 2017

Systemic lupus erythematosus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Systemic lupus erythematosus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Lupus and Quality of Life

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Systemic lupus erythematosus laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Systemic lupus erythematosus laboratory tests

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Systemic lupus erythematosus laboratory tests

on Systemic lupus erythematosus laboratory tests

Systemic lupus erythematosus laboratory tests in the news

Blogs onSystemic lupus erythematosus laboratory tests

Directions to Hospitals Treating Systemic lupus erythematosus

Risk calculators and risk factors for Systemic lupus erythematosus laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]

Overview

Laboratory findings consistent with the diagnosis of systemic lupus erythematosus include autoantibody elevation of ANA, anti-dsDNA antibody, anti-SM antibody, and antiphospholipid antibodies, and a decrease in complement levels. Nonspecific laboratory findings include mild pancytopenia, elevated levels of creatinine and proteinuria due to renal failure (secondary to nephritis), elevated levels of ESR and CRP as acute phase reactants, decreased level of complements, and positive direct Coombs test.

Laboratory tests

Laboratory findings consistent with the diagnosis of systemic lupus erythematosus include autoantibody elevation of ANA, anti-dsDNA antibody, anti-SM antibody and antiphospholipid antibodies. However, decrease of complement levels is a common finding in SLE.[1][2][3][4][5][6][7]

Laboratory changes in SLE:

Exam type Lab exam Result Clinical correlation
Hematology Complete blood count
  • Non-specific
  • May be related to constitutional symptoms
Serum creatinine Elevated
Amylase Elevated
Lipase
Urine Urinalysis
Urine sediment
Serology ANA Elevated
  • Positive in virtually all patients with SLE at some time in the course of their disease
Antiphospholipid antibodies
Complement levels
  • C3: Vary between varying between normal to slightly reduced
  • C4: Reduced
  • CH50: Reduced
Erythrocyte sedimentation rate (ESR) Elevated
  • Non-specific
C-reactive protein (CRP) Elevated
  • Non-specific
Urine protein-to-creatinine ratio Elevated
Anti-dsDNA antibody Elevated
  • Highly specific for SLE
  • As high as 70% of patients
Anti-SM antibodies Elevated
  • Highly specific for SLE
  • Positive in 30% of patients
  • Lack sensitivity
Anti-Ro/SSA antibodies Elevated
Anti-La/SSB antibodies Elevated
Anti-U1 RNP antibodies Elevated
Antiribosomal P protein antibodies Elevated
  • High specificity for SLE & low sensitivity for SLE
  • Lack specificity for involvement of a particular organ system or disease manifestation
Direct Coombs' test Positive

If the initial ANA test is negative, but the clinical suspicion of SLE is high, then additional antibody testing may still be appropriate. This is partly related to the differences in the sensitivity and specificity among the methods used to detect ANA.

Laboratory exams to distinguish SLE from other diseases

Test Interpretation
Anti-cyclic citrullinated peptide (CCP) antibodies
Rheumatoid factor (RF)
  • Less diagnostic since only 20 to 30 percent of people with SLE have a positive RF
  • Consider RA
Serological studies for infection
Creatine kinase (CK)

A more detailed look into auto-antibodies in SLE

Antibodies Prevalence Association with disease activity Pathogenesis involvement
ANA 80 - Cutaneous lupus erythematosus
dsDNA 70 -/+ Lupus nephritis
Anti-Sm antibodies 30 - Renal, neurologic, vasculitis and hematologic diseases
snRNP (U1 RNP) 30-40 - -
SSA/Ro 30 - Neonatal lupus
SSB/La 20 - Neonatal lupus
Antiribosomal P protein antibodies 20 - Neuro-psychiatric disease, liver disease
RF 20 - -

References

  1. ↑ Tan EM (1989). "Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology". Adv. Immunol. 44: 93–151. PMID 2646863.
  2. ↑ Willitzki A, Hiemann R, Peters V, Sack U, Schierack P, Rödiger S, Anderer U, Conrad K, Bogdanos DP, Reinhold D, Roggenbuck D (2012). "New platform technology for comprehensive serological diagnostics of autoimmune diseases". Clin. Dev. Immunol. 2012: 284740. doi:10.1155/2012/284740. PMC 3536031. PMID 23316252.
  3. ↑ Li J, Leng X, Li Z, Ye Z, Li C, Li X, Zhu P, Wang Z, Zheng Y, Li X, Zhang M, Tian XP, Li M, Zhao J, Zhang FC, Zhao Y, Zeng X (2014). "Chinese SLE treatment and research group registry: III. association of autoantibodies with clinical manifestations in Chinese patients with systemic lupus erythematosus". J Immunol Res. 2014: 809389. doi:10.1155/2014/809389. PMC 4017718. PMID 24864270.
  4. ↑ Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O, Komisar O, Slonimsky E, Klang E, Lotan E, Welt M, Marai I, Shina A, Amital H, Shoenfeld Y (2015). "A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients". Autoimmun Rev. 14 (1): 75–9. doi:10.1016/j.autrev.2014.10.003. PMID 25449682.
  5. ↑ Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006). "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)". J. Thromb. Haemost. 4 (2): 295–306. doi:10.1111/j.1538-7836.2006.01753.x. PMID 16420554.
  6. ↑ Truedsson L, Bengtsson AA, Sturfelt G (2007). "Complement deficiencies and systemic lupus erythematosus". Autoimmunity. 40 (8): 560–6. doi:10.1080/08916930701510673. PMID 18075790.
  7. ↑ Benito-Garcia E, Schur PH, Lahita R (2004). "Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests". Arthritis Rheum. 51 (6): 1030–44. doi:10.1002/art.20836. PMID 15593352.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Systemic_lupus_erythematosus_laboratory_tests&oldid=1334396"